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Introduction
Over the course of the next few decades, DNA sequencing will lead to each baby's genome being sequenced, and used to shape a lifetime of personalized strategies for disease prevention, detection and treatment.
FS Collins, Wall Street Journal, July 8, 2014. Within the past year, the director of the NIH updated the 1990s projection by Walter Gilbert, who postulated that by 2030-2040 the parents of every newborn child in the developed world would leave the hospital with their child's genome on a CD-ROM.
The analytic cost of whole human genome (WGS) and whole exome sequencing (WES) continues to out--pace Moore's law and is currently approaching $1,000 for WGS. Given the high burden of treatable genetic diseases in children, there is considerable interest in using WGS to diagnose and treat genetic diseases of infancy, both as an extension of current newborn screening programs (NBS) and as a pioneering implementation of precision medicine for affected infants. Early diagnosis of genetic diseases can dramatically decrease morbidity and mortality, as evidenced by current, federally mandated newborn screening (NBS) programs for ~60 treatable genetic diseases, which identifies ~5000 affected babies per year at ~10 days of life. With the emergence of WGS and whole exome sequencing, the National Institutes of Health and state NBS programs are considering the value of genome sequence information in addition to currently performed tests with the goal of improving accuracy, reducing false positives and false negatives, or identifying disorders not currently screened for.
For NBS programs, some diseases screened for currently have positive predictive values well below 5%, so improving specificity could have a substantial positive societal impact. In order to evaluate the use of deep sequencing within context of newborns has many technical, computational, informatics and ethical questions that have arisen. This workshop will focus on challenges of population based genetic sequence diagnosis for newborn disorders, the future possibilities of WGS as an enabling technology for lifelong precision medicine, and current experience with use of diagnostic WGS in the delivery of precision medicine in acutely ill infants. The challenges addressed include:
• Determination whether accurate genome or exome sequences can be obtained using existing blood spot material and testing pipelines.
• Improvement in the annotation of pathogenic genetic variants in genes associated with metabolic and other disorders.
• Evaluation of whether genetic information can reduce false positive and false negative rates by identifying cases of nonpathogenic variants and heterozygous carriers of who are not anticipated to have symptomatic disease. • Collection of patient-level rich phenotypic data through ontologies (and other means) and integration into national repositories and the electronic medical record.
• Improved capture and diagnosis of undiagnosed and affected infants for whom early intervention is warranted to minimize morbidity and mortality.
• Selection of disorders for screening, including and beyond the 31 conditions recommend by the HRSA advisory committee • Ethical challenges surrounding widespread sequencing and storing genetic data of children for clinical diagnosis.
• Public education and engagement.
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Title: Newborn screening and genome sequencing
Newborn screening for inborn errors of metabolism was first instituted in the 1960's for phenylketonuria using blood obtained from newborns that is soaked into filter paper. Screening expanded over the next 30 years by the introduction of individual tests designed to screen for individual disorders until the 1990s when tandem mass spectroscopy (MS/MS) was first applied. MS/MS allows the identification of many disorders in parallel using a single assay that measures a host of abnormal metabolites in the newborn blood spot. The NSIGHT project, a four-site project funded by NICHD and NHGRI, is now looking at a potential next step in newborn screening: identifying many more actionable, treatable diagnoses in the newborn period through exome or genome sequencing of newborn blood spot DNA. Outstanding questions include:
• the positive predictive value of abnormalities found in newborn screening, • sequencing's utility and cost as compared to standard mass spectroscopic methods to see whether it could replace standard screening, • if not replacing current screening, could sequencing complement standard screening methods and make them more specific, and • finally to explore the ethical and legal aspects of generating sequence information from newborns under a nearly mandatory public health regimen when some of these data may have significant medical relevance but are not germane to the mission of newborn screening. 
Title: Analysis challenges of newborn genome sequences
A hallmark of current newborn screening programs is their outstanding sensitivity with false negatives on the order of one per million babies screened and impressive specificity. Both the sensitivity and the specificity are essential in order, respectively, to meet the public health goals of the program at a reasonable financial and human cost. This is achieved in large part through careful optimization of highly-sensitive mass spectrometry instruments which are detecting a molecular intermediate phenotype resulting from the genetic abnormalities. Identifying such diseases from genetic information is intrinsically more challenging. The analytic instrumentation for genome variant calling is less mature than the mass spec technology. More importantly, identifying disease phenotypes from genotypes can be vastly more challenging than identifying disease phenotypes from molecular phenotypes. Preparatory studies have revealed widespread limitations of even the most authoritative databases of mutations causing those diseases incorporated in newborn screening; they have numerous variants reported as pathogenic that are present in unaffected individuals. It seems likely that they also overlook variants that may cause disease. Computational predictive methods fare far worse. Health disparities may arise due to differential ability to reliably identify pathogenic mutations in individuals from different ethic backgrounds. This talk will include progress on methods to overcome these challenges, and approaches that may help present genome sequencing as a useful technology associated with newborn screening. 
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